The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
"We are pleased the FDA has accepted our NDA for Bumetanide Nasal Spray," said Benjamin Esque, CEO of Corstasis Therapeutics ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.